Upcoming Expected Catalysts (Businesswire) - Nov 12, 2025 - "First patient enrolled in COYA 302 ALSTARS Trial; First patient dosed in COYA 302 ALSTARS Trial; Upon first patient dosing of COYA 302 in ALS, expect to receive $4.2 million milestone payment from strategic partner, Dr. Reddy's Laboratories (DRL)...ALS Biomarker data. Publication of longitudinal data on Neurofilament Light Chain (NfL) and oxidative stress markers in patients with ALS; Report additional single cell proteomics data from the completed investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD); Top-line clinical data release for an investigator-initiated trial combining LD IL-2 + CTLA4-Ig in patients with FTD; IND submission for FTD anticipated in Q4 2025."
Clinical data • Financing • IND • Trial status • Amyotrophic Lateral Sclerosis • Frontotemporal Lobar Degeneration
|